摘要
目的探讨CA199、CEA、CA125联合B超、增强CT、MRI在胰腺癌诊断中的价值。方法对82例确诊的胰腺癌患者进行回顾性分析,术前检测血清CA19-9、CEA、CA125值,行B超、增强CT和MRI单项或多项检查,对检查结果进行分析。结果胰腺癌患者血清中CA19-9、CEA、CA125水平较正常人均有明显升高(P<0.05),三种肿瘤标志物联合检测的敏感性最高(93.9%)。增强CT和MRI对胰腺癌的确诊率显著高于B超(P<0.05),而增强CT和MRI之间差异无统计学意义(P>0.05)。结论 CA19-9、CEA、CA125三种肿瘤标志物同时检测联合增强CT或MRI可提高胰腺癌的诊断率。
Objective To explor the diagnostic value of detection of serum CA19-9,CEA and CA125 with B-ultrasound sonography,enhancement computed tomography（CT） and magnetic resonance imaging（MRI） in patients with pancreatic cancer.Methods The level of serum CA19-9,CEA and CA125 were detected and one or more.methods of B-ultrasound sonography,enhancement CT and MRI were performed in 82 cases of pancreatic cancer confirmed by surgery and pathology.The results were analyzed.Results Compared to ordinary person,the level of serum CA19-9,CEA and CA125 in patients with pancreatic cancer were markedly elevated.The combination of CA19-9,CEA and CA125 could increase the sensitivity to 93.9%.A definitive diagnosis was attainable in a higher percentage of patients with enhancement CT and MRI than patients with B-ultrasound sonography.There was no significant difference between enhancement CT and MRI in the definitive diagnosis of pancreatic cancer.Conclusion The combination of CA19-9,CEA and CA125 with enhancement CT or MRI can promote the diagnostic rate in patients with pancreatic cancer.
出处
《四川医学》
CAS
2013年第7期926-928,共3页
Sichuan Medical Journal
